Editorial scope: This guide addresses analytical evidence, documentation, and research-procurement literacy. Conclusions are limited to the records and methods discussed.

Start with the name: IGF-1 LR3 is not native IGF-1

IGF-1 LR3, also written Long R3 IGF-I or Long-[Arg3]IGF-I, is a recombinant analogue of human insulin-like growth factor I. It combines two changes: glutamic acid at position 3 is replaced by arginine, and a 13-amino-acid extension is attached to the amino terminus. Native mature human IGF-I contains 70 amino acids; the Long R3 construct contains 83.

Those modifications were designed to alter interactions with insulin-like growth factor-binding proteins, usually abbreviated IGFBPs. They do not make LR3 a longer-lasting version of native IGF-1 in every biological setting, and they do not make the names interchangeable. The analogue can show different apparent potency, distribution, clearance, and feedback effects depending on the experimental system.

This article reviews molecular, cell, and animal evidence without providing a dose, route, administration method, treatment recommendation, or research protocol. Supplier listings are considered only as laboratory-procurement records and do not establish suitability for human or veterinary use.

  • Native IGF-I: the endogenous 70-amino-acid growth factor
  • Mecasermin: recombinant human IGF-1 used in a specific FDA-approved drug product
  • IGF-1 LR3: an 83-amino-acid experimental analogue with an Arg3 substitution and N-terminal extension
  • IGF-1 DES: a different truncated analogue that should not be grouped with LR3

The analogue was engineered to probe binding-protein biology

The original Long IGF-I analogue work compared several recombinant constructs in cell systems that differed in production of IGF-binding proteins. Long-[Arg3]IGF-I was especially potent in cell lines that secreted binding proteins, but it was less potent than native IGF-I in a cell line without detectable IGFBP secretion. That pattern supported the interpretation that reduced IGFBP association—not simply stronger receptor activation—was driving much of the apparent potency difference.

Binding experiments later reported that LR3 had dramatically lower affinity for several IGFBPs while retaining activity at the type 1 IGF receptor. Lower binding-protein affinity can increase the freely available fraction in some assays, but it can also increase clearance and change tissue exposure in living animals. The result depends on the model, endogenous binding proteins, nutrient state, and time scale.

Calling LR3 a universally more potent or longer-acting IGF-1 therefore collapses several separate measurements. Potency in one cell assay, persistence in circulation, receptor affinity, and total biological effect are not the same property.

Cell studies establish signaling activity, not clinical outcomes

In L6 rat myoblasts, Long-[Arg3]IGF-I stimulated protein and DNA synthesis and inhibited protein breakdown more strongly than native IGF-I under the tested culture conditions. Human fibroblast studies likewise used LR3 to show how locally produced IGFBPs can restrain IGF-mediated proliferation. Other cell experiments have examined cardiomyocytes, chondrocytes, ovarian cells, macrophage precursors, mammary cells, and biopharmaceutical production cell lines.

These experiments make LR3 useful as a mechanistic reagent. Because it interacts weakly with many binding proteins, researchers can use it to separate receptor-mediated effects from IGFBP-dependent regulation. Commercial cell-culture media have also used LR3 as an insulin or IGF pathway stimulant for protein-production systems.

A cell-proliferation result is not evidence of muscle gain, recovery, longevity, or safety in an intact organism. Culture concentration, cell lineage, receptor abundance, binding-protein secretion, nutrient composition, and exposure time all shape the result.

Cell growth is biologically relevant and also a safety uncertainty

IGF-I receptor signaling can activate pathways involving PI3K-AKT and ERK that regulate survival, metabolism, and proliferation. In fetal sheep cardiomyocytes, LR3 increased DNA-synthesis measurements, and blocking either ERK or PI3K eliminated that response. In breast-cancer cells, LR3 more strongly opposed apoptosis induced by IGFBP-3 or an antiestrogen than native IGF-I under the reported conditions.

Those findings do not mean that an LR3 research material causes or treats cancer in humans. They do show why growth-factor activity cannot be summarized as selectively anabolic. A signal that supports survival or proliferation in one desired cell population may have different consequences in another.

Mechanistic potency should therefore increase—not reduce—the need for model-specific interpretation, impurity control, and a clear separation between laboratory findings and unsupported human claims.

Rodent studies show organ and tissue effects rather than simple muscle selectivity

Early rat studies reported that LR3 was more potent than native IGF-I for selected anabolic and growth endpoints, particularly when endogenous IGFBPs limited native IGF-I activity. The affected tissues were not confined to skeletal muscle. Gastrointestinal growth and changes in organ weights appeared repeatedly in the animal literature.

In female guinea pigs, short-term LR3 exposure increased the relative weights of the adrenals, intestine, kidneys, and spleen without increasing overall body-weight gain or improving carcass composition. In rats receiving restricted food, LR3 improved nitrogen retention and modestly affected body weight but did not preserve skeletal-muscle protein. Adult rats in that study showed increased protein breakdown and reduced protein synthesis in muscle.

These results undermine a simple 'muscle-building peptide' interpretation. Organ growth, body weight, nitrogen balance, muscle protein synthesis, and muscle retention are distinct endpoints, and a favorable change in one cannot stand in for the others.

Large-animal findings were inconsistent and nutrient-dependent

Studies in pigs, calves, cattle, and sheep produced different outcomes. In neonatal pigs, LR3 increased growth only under selected feeding conditions and did not consistently outperform control or native IGF-I. A separate finisher-pig study reported reduced food intake, daily gain, circulating insulin, growth hormone, IGF-I, and IGFBP-3 during LR3 exposure.

Neonatal-calf studies reported changes in glucose, insulin, endogenous IGF-I, IGFBP-2, and growth-hormone patterns. Oral exposure did not reproduce the endocrine effects observed with parenteral exposure in that model. Beef-heifer and fetal-sheep work further showed that species, developmental stage, and nutritional status change the response.

This heterogeneity is not a technical footnote. It demonstrates that the altered binding-protein profile does not generate one predictable whole-organism outcome. Results from a single species or tissue should not be generalized to people.

Glucose and endocrine feedback are part of the evidence

IGF-I and insulin signaling overlap, and LR3 has produced glucose and endocrine changes in animal studies. Neonatal calves exposed systemically showed lower plasma glucose and insulin, while several models reported suppression of endogenous IGF-I, growth hormone, or circulating binding proteins.

Those observations matter because a growth signal can alter feedback throughout the somatotropic and metabolic systems. A catalog statement about IGF-1 receptor activity does not describe the downstream endocrine state of an intact organism.

The approved mecasermin label provides additional context for the native recombinant IGF-1 pathway: its warnings include severe hypoglycemia, lymphoid-tissue hypertrophy, intracranial hypertension, orthopedic complications, and malignant-neoplasia concerns. Those product-specific data cannot be assigned directly to LR3, but they make clear that IGF-pathway activity is not a narrow muscle endpoint.

Tumor-bearing animal models highlight nonselective growth signaling

In a tumor-bearing rat model, LR3 did not improve carcass-protein accretion and changes in muscle protein turnover tracked with tumor burden. A later mouse cachexia study reported that LR3 limited muscle-mass loss but accelerated tumor growth.

These are disease-specific animal models, not human safety studies. They cannot quantify cancer risk for a person or establish an effect across tumor types. They do, however, illustrate a central biological limitation: activating a broadly expressed growth-factor pathway may affect both host tissue and tumor tissue.

Any claim that LR3 is selectively anabolic, free of proliferative concerns, or safer because it is 'research grade' goes beyond the evidence. Grade language and chromatographic purity do not resolve receptor-level biological risk.

Human evidence for IGF-1 LR3 is not established

The LR3 literature identified for this review consists predominantly of biochemical, cell-culture, and animal studies. Searches of PubMed and ClinicalTrials.gov did not identify a controlled human therapeutic trial program for Long R3 IGF-I. Papers involving human-derived cells are not human clinical studies.

A 2010 analytical case report identified a His-tagged Long R3 IGF-I-like protein in a black-market vial. That study demonstrated what mass spectrometry could identify in one seized product; it did not study effectiveness or safety. The authors specifically noted that the effects of the His-tagged material in humans had not been described.

Without controlled human pharmacokinetic, dose-ranging, safety, and outcome studies, animal potency cannot be converted into a human benefit estimate. The absence of a modern clinical development record is a major evidence boundary, not a blank space that supplier marketing can fill.

Mecasermin approval does not transfer to LR3

INCRELEX is an FDA-approved prescription product containing mecasermin, recombinant human IGF-1, for a narrowly defined pediatric growth-failure indication. Its approval applies to that active ingredient, formulation, manufacturing controls, labeling, and studied population.

IGF-1 LR3 has a different sequence and binding-protein profile. It is not mecasermin, is not a generic form of INCRELEX, and does not inherit the approved product's evidence or regulatory status. FDA's substance database lists Long-(Arg3) insulin-like growth factor-I as an ingredient substance, but substance registration and a UNII do not constitute drug approval.

The same distinction applies in reverse: adverse-event rates and pharmacokinetics from mecasermin cannot simply be pasted onto LR3. They provide pathway context while leaving LR3-specific human safety unresolved.

Sport rules and drug approval answer different questions

The 2026 World Anti-Doping Agency Prohibited List includes IGF-1, mecasermin, and IGF-1 analogues among prohibited growth factors and growth-factor modulators. LR3 falls within that analogue category for sport-rule purposes.

A substance can be prohibited in sport without being an approved drug, and drug approval does not determine whether a substance is prohibited in competition. These are separate systems with different purposes.

For research procurement, WADA status is contextual information rather than analytical proof. It does not authenticate a vial, establish purity, or validate a supplier's claim.

Supplier documentation must establish the exact recombinant product

LR3 is a folded recombinant protein analogue with three intramolecular disulfide bonds, not merely a short linear peptide name. Useful documentation should define the complete 83-residue sequence, Arg3 substitution, 13-residue extension, terminal chemistry, disulfide connectivity, expected intact mass, expression system, purification tags or linkers, and lot-specific test results.

The black-market case report is especially instructive: investigators identified a C-terminal His tag and linker that were not part of ordinary Long R3 IGF-I identity. A mass result near an expected value is not enough if an undeclared tag, truncation, oxidation product, misfolded form, or aggregate is present. Peptide mapping or high-resolution intact and digested mass analysis can provide stronger structural evidence than a generic purity screenshot.

Chromatographic purity remains a separate measurement from identity, correct folding, biological activity, concentration, sterility, endotoxin, and stability. A certificate can report tests on a sample; it cannot prove clinical equivalence, safety, or that the public document matches the material actually received.

  • Sequence identity: all 83 residues and the Arg3 substitution
  • Structural identity: expected disulfide connectivity and folding evidence
  • Recombinant process: expression host, purification method, and tag-removal status
  • Purity and variants: intact product, fragments, oxidized forms, aggregates, and host-cell impurities
  • Lot traceability: report number, dates, sample identifier, and match to the offered lot

Evidence-stage summary

Molecular evidence: Long R3 IGF-I is a defined 83-amino-acid IGF-I analogue engineered for reduced binding to many IGFBPs while retaining IGF-I receptor activity.

Cell evidence: LR3 is a useful mechanistic and bioprocess reagent and can stimulate survival, proliferation, and protein-turnover pathways under selected culture conditions. Those findings do not establish organism-level selectivity.

Animal evidence: LR3 produced tissue growth, endocrine, glucose, and protein-turnover effects, but outcomes varied by species, age, nutrition, and disease model. Increased organ growth and accelerated tumor growth appeared in some models.

Human evidence: no controlled therapeutic trial program was identified. FDA approval for mecasermin does not apply to LR3, and supplier documentation cannot replace clinical evidence.

FAQ: Is IGF-1 LR3 the same as IGF-1 or mecasermin?

No. IGF-1 LR3 contains an Arg3 substitution and a 13-amino-acid N-terminal extension, giving it 83 residues instead of the 70 in mature human IGF-I. Mecasermin is recombinant human IGF-1 used in a specific approved product; LR3 is a distinct experimental analogue.

FAQ: Does IGF-1 LR3 have human clinical evidence?

No controlled human therapeutic trial program was identified in PubMed or ClinicalTrials.gov for Long R3 IGF-I. The published evidence is predominantly biochemical, cell-based, and animal research, so human benefit and safety cannot be inferred.

FAQ: What should an IGF-1 LR3 certificate establish?

At minimum, documentation should connect the tested lot to the complete LR3 sequence, expected intact mass, recombinant process, tag status, purity result, and relevant variant or aggregate testing. A high HPLC percentage alone does not establish correct identity, folding, potency, sterility, or suitability for any use.

Sources and further reading

Primary and standards-based sources used to frame this educational overview:

Explore related resources

Peptide Due Diligence Research Brief

Keep the evidence in view.

Receive concise briefings on analytical testing, documentation quality, supplier transparency, and new additions to the research library.

By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.

Already subscribed? Get your free field guide.

Continue your due diligence